HPV & co. in sporadic breast cancer: any connection?

Breast cancer; Oncoviruses; Human mammary tumor virus (HMTV); Human papillomavirus (HPV); Epstein-Barr virus (EBV); Cytomegalovirus (CMV); Polyomaviruses

[1] Roncati L. Adjuvant metronomic chemotherapy after surgery in pT1–T2 N0 M0 HER2-positive and ER/PR-positive breast cancer plus targeted therapy, anti-hormonal therapy, and radiotherapy, with or without immunotherapy: a new operational proposal. Cancers. 2025; 17: 1323.

[2] Obeagu EI, Obeagu GU. Breast cancer: a review of risk factors and diagnosis. Medicine. 2024; 103: e36905.

[3] Lalloo F, Evans DG. Familial breast cancer. Clinical Genetics. 2012; 82: 105–114.

[4] Taneja P, Frazier DP, Kendig RD, Maglic D, Sugiyama T, Kai F, et al. MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Review of Molecular Diagnostics. 2009; 9: 423–440.

[5] Liu B, Wang Y, Melana SM, Pelisson I, Najfeld V, Holland JF, et al. Identification of a proviral structure in human breast cancer. Cancer Research. 2001; 61: 1754–1759.

[6] Awan UA, Bashir S, Hassan U, Khan SN, Awan FM, Jabbar A, et al. HPV-driven breast carcinogenesis: associations with tumor severity, Ki67 expression and metastasis. Infectious Agents and Cancer. 2025; 20: 55.

[7] Kan CY, Iacopetta BJ, Lawson JS, Whitaker NJ. Identification of human papillomavirus DNA gene sequences in human breast cancer. British Journal of Cancer. 2005; 93: 946–948.

[8] de Moraes FCA, Wagner PHS, da Silva ABN, Magalhães MCF, Burbano RMR. Does Epstein-Barr virus contribute to breast cancer risk worldwide? A systematic review and meta-analysis. Clinical Breast Cancer. 2025. PMID: 40841281.

[9] Blanchard A, Elmalih N, Muganda P. Differential expression of Epstein-Barr virus sequences in various breast cancer subtypes. Genes. 2025; 16: 756.

[10] Ghaffari H, Tavakoli A, Nafissi N, Farahmand M, Ghorbani S, Moochani SS, et al. Human cytomegalovirus and Epstein-Barr virus infections in breast cancer: a molecular study on Iranian women. Breast Disease. 2021; 40: 227–233.

[11] Richardson AK, Currie MJ, Robinson BA, Morrin H, Phung Y, Pearson JF, et al. Cytomegalovirus and Epstein-Barr virus in breast cancer. PLOS ONE. 2015; 10: e0118989.

[12] Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, et al. HPV DNA frequency and subset analysis in human breast cancer patients’ normal and tumoral tissue samples. Journal of Experimental & Clinical Cancer Research. 2006; 25: 515–521.

[13] Khasawneh AI, Himsawi N, Sammour A, Al Shboul S, Alorjani M, Al-Momani H, et al. Association of human papilloma virus, cytomegalovirus, and Epstein-Barr virus with breast cancer in Jordanian women. Medicina. 2024; 60: 699.

[14] Gupta I, Jabeen A, Al-Sarraf R, Farghaly H, Vranic S, Sultan AA, et al. The co-presence of high-risk human papillomaviruses and Epstein-Barr virus is linked with tumor grade and stage in Qatari women with breast cancer. Human Vaccines & Immunotherapeutics. 2021; 17: 982–989.

[15] Al Moustafa AE, Al-Antary N, Aboulkassim T, Akil N, Batist G, Yasmeen A. Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in Syrian women with breast cancer. Human Vaccines & Immunotherapeutics. 2016; 12: 1936–1939.

[16] Aguayo F, Khan N, Koriyama C, González C, Ampuero S, Padilla O, et al. Human papillomavirus and Epstein-Barr virus infections in breast cancer from chile. Infectious Agents and Cancer. 2011; 6: 7.

[17] Majeed HM, Kadhum SJ, Majeed HM. Association of cytomegalovirus and high-risk human papillomavirus with breast cancer progression. Cellular and Molecular Biology. 2025; 71: 61–65.

[18] Glenn WK, Whitaker NJ, Lawson JS. High risk human papillomavirus and Epstein Barr virus in human breast milk. BMC Research Notes. 2012; 5: 477.

[19] Yoshida K, Furumoto H, Abe A, Kato T, Nishimura M, Kuwahara A, et al. The possibility of vertical transmission of human papillomavirus through maternal milk. Journal of Obstetrics and Gynaecology. 2011; 31: 503–506.

[20] Khasawneh AI, Himsawi N, Alorjani M, Al-Momani H, Shahin U, Sammour A, et al. Triple viral infections in advanced breast cancer: insights from a three-case report and literature review. Diagnostics. 2024; 15: 51.

[21] Gupta I, Ulamec M, Peric-Balja M, Ramic S, Al Moustafa A, Vranic S, et al. Presence of high-risk HPVs, EBV, and MMTV in human triple-negative breast cancer. Human Vaccines & Immunotherapeutics. 2021; 17: 4457–4466.

[22] Corbex M, Bouzbid S, Traverse-Glehen A, Aouras H, McKay-Chopin S, Carreira C, et al. Prevalence of papillomaviruses, polyomaviruses, and herpesviruses in triple-negative and inflammatory breast tumors from Algeria compared with other types of breast cancer tumors. PLOS ONE. 2014; 9: e114559.

[23] Piana AF, Sotgiu G, Muroni MR, Cossu-Rocca P, Castiglia P, De Miglio MR. HPV infection and triple-negative breast cancers: an Italian case-control study. Virology Journal. 2014; 11: 190.

[24] Roncati L. Ozone-oxygen therapy to prevent HPV-related cancers of the lower gynecological tract in infected patients: the rationale for further developments. Cancers. 2025; 17: 543.

[25] Alinezhadi M, Makvandi M, Kaydani GA, Jazayeri SN, Charostad J, Talaeizadeh AT, et al. Detection of high-risk human papillomavirus DNA in invasive ductal carcinoma specimens. Asian Pacific Journal of Cancer Prevention. 2022; 23: 3201–3207.

[26] Liang W, Wang J, Wang C, Lv Y, Gao H, Zhang K, et al. Detection of high-risk human papillomaviruses in fresh breast cancer samples using the hybrid capture 2 assay. Journal of Medical Virology. 2013; 85: 2087–2092.

[27] Yu Y, Morimoto T, Sasa M, Okazaki K, Harada Y, Fujiwara T, et al. Human papillomavirus type 33 DNA in breast cancer in Chinese. Breast Cancer. 2000; 7: 33–36.

[28] Yasmeen A, Bismar TA, Kandouz M, Foulkes WD, Desprez PY, Al Moustafa AE. E6/E7 of HPV type 16 promotes cell invasion and metastasis of human breast cancer cells. Cell Cycle. 2007; 6: 2038–2042.

[29] Wang YW, Zhang K, Zhao S, Lv Y, Zhu J, Liu H, et al. HPV status and its correlation with BCL2, p21, p53, Rb, and survivin expression in breast cancer in a Chinese population. BioMed Research International. 2017; 2017: 6315392.

[30] Sangthong J, Thuwajit C, Jensen LT, Komyod W, Yuvaniyama J, Ponglikitmongkol M. BRCA1 deficiency enhances the aggressiveness of breast cancer cells expressing HPV16 oncoproteins. Biology of the Cell. 2024; 116: e202300072.

[31] Charostad J, Azaran A, Nakhaei M, Astani A, Kaydani GA, Motamedfar A, et al. Upregulation of inter-leukin-6 in HPV-positive breast cancer patients. Iranian Journal of Immunology. 2021; 18: 315–330.

[32] Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, et al. Human papillomavirus detected in female breast carcinomas in Japan. British Journal of Cancer. 2008; 99: 408–414.

[33] Choi YL, Cho EY, Kim JH, Nam SJ, Oh YL, Song SY, et al. Detection of human papillomavirus DNA by DNA chip in breast carcinomas of Korean women. Tumor Biology. 2007; 28: 327–332.

[34] Fu L, Wang D, Shah W, Wang Y, Zhang G, He J. Association of human papillomavirus type 58 with breast cancer in Shaanxi province of China. Journal of Medical Virology. 2015; 87: 1034–1040.

[35] Lin C, Tsai SC, Huang JY, Lin FC. HPV infection and breast cancer risk: insights from a nationwide population study in Taiwan. Frontiers in Oncology. 2023; 13: 1210381.

[36] Naushad W, Surriya O, Sadia H. Prevalence of EBV, HPV and MMTV in Pakistani breast cancer patients: a possible etiological role of viruses in breast cancer. Infection, Genetics and Evolution. 2017; 54: 230–237.

[37] Sigaroodi A, Nadji SA, Naghshvar F, Nategh R, Emami H, Velayati AA. Human papillomavirus is associated with breast cancer in the north part of Iran. The Scientific World Journal. 2012; 2012: 837191.

[38] Ali SH, Al Alwan NA, Al Alwany SH. Detection and genotyping of human papillomavirus in breast cancer tissues from Iraqi patients. Eastern Mediterranean Health Journal. 2014; 20: 372–377.

[39] Akil N, Yasmeen A, Kassab A, Ghabreau L, Darnel AD, Al Moustafa A. High-risk human papillomavirus infections in breast cancer in Syrian women and their association with Id-1 expression: a tissue microarray study. British Journal of Cancer. 2008; 99: 404–407.

[40] Raouf M, Kamal S, Elsayed R, Zaki I, Kholeif D. Detection of bovine leukemia virus, Epstein-Barr virus and human papillomavirus in breast cancer tissues of Egyptian patients. Infectious Agents and Cancer. 2025; 20: 43.

[41] Metwally SA, Abo-Shadi MA, Abdel Fattah NF, Barakat AB, Rabee OA, Osman AM, et al. Presence of HPV, EBV and HMTV viruses among Egyptian breast cancer women: molecular detection and clinical relevance. Infection and Drug Resistance. 2021; 14: 2327–2339.

[42] Gebregzabher E, Seifu D, Tigneh W, Bokretsion Y, Bekele A, Abebe M, et al. Detection of high- and low-risk HPV DNA in archived breast carcinoma tissues from Ethiopian women. International Journal of Breast Cancer. 2021; 2021: 2140151.

[43] ElAmrani A, Gheit T, Benhessou M, McKay-Chopin S, Attaleb M, Sahraoui S, et al. Prevalence of mucosal and cutaneous human papillomavirus in Moroccan breast cancer. Papillomavirus Research. 2018; 5: 150–155.

[44] de León DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, Villavicencio V, et al. Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. BMC Cancer. 2009; 9: 26.

[45] Calderon G, Castaneda CA, Castillo M, Sanchez J, Bernabe L, Suarez N, et al. Human papillomavirus, cytomegalovirus infection and p16 staining in breast tumors from Peruvian women. Asian Pacific Journal of Cancer Prevention. 2022; 23: 1571–1576.

[46] Zapana EM, Vilcapoma-Diaz M, Ortiz-Muchotrigo N. Detection of human papilloma virus in breast cancer biopsies using PCR and immunohistochemistry at the Santa Rosa hospital during 2019. Revista Peruana de Medicina Experimental y Salud Pública. 2022; 39: 450–455.

[47] Cavalcante JR, Pinheiro LGP, de Almeida PRC, Ferreira MVP, Cruz GA, Campelo TA, et al. Association of breast cancer with human papillomavirus (HPV) infection in Northeast Brazil: molecular evidence. Clinics. 2018; 73: e465.

[48] Delgado-García S, Martínez-Escoriza J, Alba A, Martín-Bayón TA, Ballester-Galiana H, Peiró G, et al. Presence of human papillomavirus DNA in breast cancer: a Spanish case-control study. BMC Cancer. 2017; 17: 320.

[49] Salman NA, Davies G, Majidy F, Shakir F, Akinrinade H, Perumal D, et al. Association of high risk human papillomavirus and breast cancer: a UK based study. Scientific Reports. 2017; 7: 43591.

[50] Herrera-Goepfert R, Vela-Chávez T, Carrillo-García A, Lizano-Soberón M, Amador-Molina A, Oñate-Ocaña LF, et al. High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women. BMC Cancer. 2013; 13: 445.

[51] Duò D, Ghimenti C, Migliora P, Pavanelli MC, Mastracci L, Angeli G. Identification and characterization of human papillomavirus DNA sequences in Italian breast cancer patients by PCR and line probe assay reverse hybridization. Molecular Medicine Reports. 2008; 1: 673–677.

[52] Lawson JS, Glenn WK, Heng B, Ye Y, Tran B, Lutze-Mann L, et al. Koilocytes indicate a role for human papilloma virus in breast cancer. British Journal of Cancer. 2009; 101: 1351–1356.

[53] Reza MA, Reza MH, Mahdiyeh L, Mehdi F, Hamid ZN. Evaluation frequency of Merkel cell polyoma, Epstein-Barr and mouse mammary tumor viruses in patients with breast cancer in Kerman, southeast of Iran. Asian Pacific Journal of Cancer Prevention. 2015; 16: 7351–7357.

[54] Alipour Z, Kaydani GA, Makvandi M, Javadi M, Talaeizadeh A. Prevalence of BK and JC polyomaviruses among patients with breast cancer. Asian Pacific Journal of Cancer Prevention. 2024; 25: 821–827.

[55] Gross L. A filterable agent, recovered from Ak leukemic extracts, causing salivary gland carcinomas in C3H mice. Proceedings of the Society for Experimental Biology and Medicine. 1953; 83: 414–421.